Prostate Cancer

A phase III study of abiraterone acetate in chemotherapy-naive patients with mCRPC has been unblinded following a positive interim analysis.

A meta-analysis shows no apparent association between androgen deprivation therapy and cardiovascular events and death in men with prostate cancer.

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

Annual prostate cancer screening does not decrease mortality from prostate cancer more than opportunistic screening.

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223

In March, a one-day conference will provide specialists with practical information they need to provide their patients with the best in diagnostic and therapeutic care.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the NeoACT Sipuleucel-T Study

Radiation therapy added to androgen deprivation therapy prolongs overall survival in men with locally advanced or otherwise high-risk prostate cancer.

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

In order to design new treatments for prostate cancer and prolong the lives of patients with the disease, researchers are going to have to delve into the tumor microenvironment.

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Men with prostate cancer now have an array of treatments, which was not the case a decade ago.

Not all intermediate-risk prostate cancer patients benefit from the addition of androgen deprivation therapy to radiation therapy.

The investigational compound tasquinimod significantly postpones disease progression and increases PFS in men with minimally symptomatic, metastatic CRPC.

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

Dr. Christopher Logothetis, from the MD Anderson Cancer Center, Discusses Prostate Cancer Therapy

Dr. Leonard Gomella, from Kimmel Cancer Center, Discusses Androgen-Deprivation Therapy

Delivering higher doses of external beam radiation in a shorter period of time was as effective as conventional radiation in preventing treatment failure in men with intermediate- to high-risk prostate cancer.

Radium-223, an alpha-emitting radiopharmaceutical, has been shown to improve overall survival (OS) in men with metastatic castrationresistant prostate cancer (mCRPC) in an interim analysis of the ALSYMPCA trial.

Middle-aged men taking a class of drugs called statins to reduce cholesterol levels were shown to have reduced the risk of mortality due to prostate cancer by approximately 50%, according to a new study...

Dr. Oliver Sartor, from Tulane Cancer Center, Describes Patients in the ALSYMPCA Radium-223 Trial

The rate of hospitalization in older men within 30 days of a prostate biopsy is more than double that occurring in a control population not undergoing a biopsy.

A single dose of radiotherapy and a single injection of ibandronate provided similar pain relief from bone metastases in men with metastatic prostate cancer.

Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.